- Home
- ZEO vs SLGL Comparison
ZEO vs SLGL Comparison
Compare ZEO & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- SLGL
- Stock Information
- Founded
- ZEO 2005
- SLGL 1997
- Country
- ZEO United States
- SLGL Israel
- Employees
- ZEO N/A
- SLGL N/A
- Industry
- ZEO
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- SLGL Health Care
- Exchange
- ZEO NYSE
- SLGL Nasdaq
- Market Cap
- ZEO 22.5M
- SLGL 21.1M
- IPO Year
- ZEO N/A
- SLGL 2018
- Fundamental
- Price
- ZEO $2.72
- SLGL $7.24
- Analyst Decision
- ZEO
- SLGL Buy
- Analyst Count
- ZEO 0
- SLGL 1
- Target Price
- ZEO N/A
- SLGL $40.00
- AVG Volume (30 Days)
- ZEO 5.4M
- SLGL 13.2K
- Earning Date
- ZEO 06-17-2025
- SLGL 05-23-2025
- Dividend Yield
- ZEO N/A
- SLGL N/A
- EPS Growth
- ZEO N/A
- SLGL N/A
- EPS
- ZEO N/A
- SLGL N/A
- Revenue
- ZEO $73,244,083.00
- SLGL $12,103,000.00
- Revenue This Year
- ZEO N/A
- SLGL N/A
- Revenue Next Year
- ZEO N/A
- SLGL $31.17
- P/E Ratio
- ZEO N/A
- SLGL N/A
- Revenue Growth
- ZEO N/A
- SLGL 603.66
- 52 Week Low
- ZEO $1.05
- SLGL $3.34
- 52 Week High
- ZEO $4.75
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- ZEO 61.23
- SLGL 50.26
- Support Level
- ZEO $2.52
- SLGL $7.15
- Resistance Level
- ZEO $3.05
- SLGL $7.45
- Average True Range (ATR)
- ZEO 0.28
- SLGL 0.32
- MACD
- ZEO 0.10
- SLGL -0.10
- Stochastic Oscillator
- ZEO 61.73
- SLGL 31.36
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.